Gastroprotective strategies in chronic NSAID users: A cost-effectiveness analysis comparing single-tablet formulations with individual components

Value in Health

Volumn 16, Issue 5, 2013, Pages 769-777

  De Groot, N L ^a   Spiegel, B M R ^b,c,d   Van Haalen, H G M ^a   De Wit, N J ^a   Siersema, P D ^a   Van Oijen, M G H ^a,d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

compliance; cost effectiveness; cost utility; drugs proton pump inhibitors; dyspepsia; gastrointestinal bleeding; nonsteroidal anti inflammatory

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ARTICLE; CHRONIC ARTHRITIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; HUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TABLET FORMULATION;

COMPLIANCE; COST-EFFECTIVENESS; COST-UTILITY; DYSPEPSIA; GASTROINTESTINAL BLEEDING; NONSTEROIDAL ANTI-INFLAMMATORY DRUGS; PROTON PUMP INHIBITORS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ARTHRITIS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; CYCLOOXYGENASE 2 INHIBITORS; DECISION SUPPORT TECHNIQUES; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; GASTROINTESTINAL DISEASES; HISTAMINE H2 ANTAGONISTS; HUMANS; MARKOV CHAINS; MEDICATION ADHERENCE; MISOPROSTOL; MODELS, ECONOMIC; PROTON PUMP INHIBITORS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84881662352     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.05.002     Document Type: Article

References (51)

1. National Institute for Health and Clinical Excellence. Osteoarthritis: The Care and Management of Osteoarthritis in Adults. NICE clinical guideline 59. London, UK: National Institute for Health and Clinical Excellence, 2008.
2. W. Zhang, M. Doherty, and N. Arden EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis 64 2005 669 681
3. L.A. Garcia Rodriguez, and T.L. Barreales Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population Gastroenterology 132 2007 498 506
4. R.M. Herings, and O.H. Klungel An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands Pharmacoeconomics 19 2001 655 665
5. F.L. Lanza, F.K. Chan, and E.M. Quigley Guidelines for prevention of NSAID-related ulcer complications Am J Gastroenterol 104 2009 728 738
6. N. Latimer, J. Lord, and R.L. Grant Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis BMJ 339 2009 b2538
7. B.M. Spiegel, C.F. Chiou, and J.J. Ofman Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups Arthritis Rheum 53 2005 185 197
8. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008;118:1894-909.
9. N.D. Yeomans, Z. Tulassay, and L. Juhasz A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group N Engl J Med 338 1998 719 726
10. F.E. Silverstein, G. Faich, and J.L. Goldstein Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study JAMA 284 2000 1247 1255
11. C. Bombardier, L. Laine, and A. Reicin Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis VIGOR Study Group. N Engl J Med 343 1520-8 2000 2 p following 1528
12. B.M. Spiegel, L. Targownik, and G.S. Dulai The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis Ann Intern Med 138 2003 795 806
13. L. Laine, L. Connors, and M.R. Griffin Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines Aliment Pharmacol Ther 30 2009 767 774
14. J.L. Goldstein, K.B. Howard, and S.M. Walton Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications Clin Gastroenterol Hepatol 4 2006 1337 1345
15. M.C. Sturkenboom, T.A. Burke, and M.J. Tangelder Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs Aliment Pharmacol Ther 18 2003 1137 1147
16. E.M. Van Soest, M.C. Sturkenboom, and J.P. Dieleman Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage Aliment Pharmacol Ther 26 2007 265 275
17. J.L. Goldstein, M.C. Hochberg, and J.G. Fort Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone Aliment Pharmacol Ther 32 2010 401 413
18. L. Laine, M. Schiff, and M. Genovese Does high-dose famotidine reduce gastric and duodenal ulcers in NSAID users? Two double-blind six month trials of single-tablet combination ibuprofen-famotidine vs ibuprofenalone (Reduce-1 and 2) Gastroenterology 136 2009 A-67
19. M.J. Al, N. Maniadakis, and E.W. Grijseels Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands Value Health 11 2008 589 599
20. L.N. Troelsen, P. Garred, and S. Jacobsen Mortality and predictors of mortality in rheumatoid arthritis - a role for mannose-binding lectin? J Rheumatol 37 2010 536 543
21. J.J. Sung, K.K. Tsoi, and T.K. Ma Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases Am J Gastroenterol 105 2010 84 89
22. R.W. Thomsen, A. Riis, and S. Christensen Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors Aliment Pharmacol Ther 24 2006 1431 1438
23. P. Emery, H. Zeidler, and T.K. Kvien Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison Lancet 354 1999 2106 2111
24. J.J. Ofman, C.H. Maclean, and W.L. Straus Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs Arthritis Rheum 49 2003 508 518
25. M.J. Langman, D.M. Jensen, and D.J. Watson Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs JAMA 282 1999 1929 1933
26. B.M. Spiegel, M. Farid, and G.S. Dulai Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis Am J Med 119 2006 448-36
27. F.E. Silverstein, D.Y. Graham, and J.R. Senior Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial Ann Intern Med 123 1995 241 249
28. E. Rahme, M. Bardou, and K. Dasgupta Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study Rheumatology (Oxford) 46 2007 265 272
29. A. Lanas, L.A. Garcia-Rodriguez, and M.T. Arroyo Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations Gut 55 2006 1731 1738
30. A. Rostom, K. Muir, and C. Dube Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review Clin Gastroenterol Hepatol 5 2007 818 828 828:e1-5; quiz 768
31. G.I. Leontiadis, A. Sreedharan, and S. Dorward Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding Health Technol Assess 11 2007 iii-164
32. J.J. Deeks, L.A. Smith, and M.D. Bradley Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials BMJ 325 2002 619
33. M.K. Patterson, J. Castellsague, and A.M. Walker Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib Pharmacoepidemiol Drug Saf 17 2008 982 988
34. P.W. Groeneveld, T.A. Lieu, and A.M. Fendrick Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia Am J Gastroenterol 96 2001 338 347
35. M.H. Ebell, L. Warbasse, and C. Brenner Evaluation of the dyspeptic patient: a cost-utility study J Fam Pract 44 1997 545 555
36. J.J. Sung, A. Barkun, and E.J. Kuipers Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial Ann Intern Med 150 2009 455 464
37. S. Loperfido, V. Baldo, and E. Piovesana Changing trends in acute upper-GI bleeding: a population-based study Gastrointest Endosc 70 2009 212 224
38. M.E. van Leerdam Epidemiology of acute upper gastrointestinal bleeding Best Pract Res Clin Gastroenterol 22 2008 209 224
39. C. Hawkey, N.J. Talley, and N.D. Yeomans Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors Am J Gastroenterol 100 2005 1028 1036
40. C.J. Hawkey, R.H. Jones, and N.D. Yeomans Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs Aliment Pharmacol Ther 25 2007 813 821
41. J. Goves, J.K. Oldring, and D. Kerr First line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacid/alginate liquid: a multicentre study in general practice Aliment Pharmacol Ther 12 1998 147 157
42. S.V. van Zanten, D. Armstrong, and N. Chiba Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER: trial Am J Gastroenterol 101 2006 2096 2106
43. F.K. Chan, L.C. Hung, and B.Y. Suen Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis N Engl J Med 347 2002 2104 2110
44. J.E. Siegel, G.W. Torrance, and L.B. Russell Guidelines for pharmacoeconomic studies: recommendations from the Panel on Cost-Effectiveness in Health and Medicine. Panel on Cost- Effectiveness in Health and Medicine Pharmacoeconomics 11 1997 159 168
45. S.M.C. Vijgen, M.C.M. Busch, and G.A. de Wit Economic evaluation of prevention: opportunities for Dutch public health policy Bilthoven, NL: RIVM 2005
46. Dutch Healthcare Authority. Available from: www.nza.nl. [Accessed February 1, 2012].
47. Health Care Insurance Board. Available from: www.medicijnkosten.nl. [Accessed February 1, 2012].
48. L. Laine, S.P. Curtis, and B. Cryer Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients Aliment Pharmacol Ther 32 2010 1240 1248
49. C. Cameron, S.V. van Zanten, and C. Skedgel Cost-utility analysis of proton pump inhibitors and other gastro-protective agents for prevention of gastrointestinal complications in elderly patients taking nonselective nonsteroidal anti-inflammatory agents Aliment Pharmacol Ther 31 2010 1354 1364
50. E.M. Van Soest, V.E. Valkhoff, and G. Mazzaglia Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases Gut 60 2011 1650 1659
51. E. de Klerk, D. van der Heijde, and R. Landewe Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout J Rheumatol 30 2003 44 54